NEW YORK – Truvian Sciences announced Wednesday that it has closed a $27.1 million Series B financing round to support the company's development of an automated benchtop system to provide lab accurate results in 20 minutes.
The financing round was led by GreatPoint Ventures and included DNS Capital, Tao Capital Partners, and existing investor Domain Associates. San Diego-based Truvian has raised $46.3 million since its founding in 2015, it said.
The benchtop system combines chemistries, immunoassays, and hematology assays in one device, and its panel will cover 40 commonly ordered diagnostic tests, including lipid and metabolic panels and a complete blood cell count, the company said in a statement. Truvian aims to submit the system to the US Food and Drug Administration for 510(k) clearance in 2020, as well as CLIA-waiver. It will also seek CE marking.
"By developing an accurate, convenient and affordable alternative to off-site labs, Truvian is poised to raise the bar for consumers by providing them with immediate insights to inform their healthcare decisions," Ashok Krishnamurthi, managing partner at GreatPoint Ventures, said in a statement.
Truvian also announced the appointment of Katherine Atkinson as chief commercial officer and Paul Meister to its board of directors.